Navigation Links
Merck's Investigational Migraine Treatment MK-0974 Significantly,Improved Migraine Pain on Several Efficacy Measures in a Phase II,Study

treatment effect of MK-0974 for each measure was significant compared to placebo (p<0.001), and included:

-- two-hour pain freedom (reduction to no pain): 45.2 percent for 300 mg, 24.3 percent for 400 mg and 32.1 percent for 600 mg of MK-0974 respectively; 33.4 percent for rizatriptan and 14.3 percent for placebo;

-- 24-hour sustained pain-relief (defined as those with pain relief at two hours with no recurrence of headache and no use of optional second dose or rescue medication during the 2-24 hour period): 52.6 percent for 300 mg, 37.8 percent for 400 mg, 52.5 percent for 600 mg of MK-0974 respectively; 35.3 percent for rizatriptan and 23.5 percent for placebo; and

-- 24-hour sustained pain-freedom (defined as those with no pain at two hours who remain free of pain during the 2-24 hour period with no use of optional second dose or rescue medication): 39.6 percent for 300 mg, 22.0 percent for 400 mg, 32.0 percent for 600 mg of MK-0974 respectively; 18.4 percent for rizatriptan and 11.0 percent for placebo.

In addition to the measure of migraine pain, MK-0974 provided relief of migraine-associated symptoms, including nausea and sensitivity to light and sound, and improved functional disability two hours post dose, as well as reduced patients' need for rescue medication. However, the study was not powered to evaluate a statistical response to these measures.

In the study, treatment with MK-0974 was generally well tolerated with no reports of serious adverse events. The most common adverse experiences occurring in patients treated with MK-0974 were nausea, dizziness and somnolence. There also were no increases in adverse events associated with increasing doses studied.

"These results provide additional evidence of the potential benefit of CGRP receptor antagonists as a new and promising class of migraine therapies," said Alan Rapoport, M.D., clinical professor of Neurology at the David Geffen School of Medicine at UCLA in Los
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. New England Journal of Medicine Publishes New Data on Gardasil, Mercks Cervical Cancer Vaccine
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
4. Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes
5. Investigational Study Demonstrated a Re-Establishment of Clinical Improvement with Orencia (Abatacept) in Children with Juvenile Idiopathic Arthritis upon Re-Introduction of Therapy
6. Data Demonstrated Metastatic Melanoma Response to Investigational Immunotherapy Ipilimumab
7. Investigational Drug Cediranib (AZD2171) Shows Promise in Patients With Recurrent Glioblastoma (GBM)
8. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
9. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
10. Investigational Cancer Drug Pertuzumab Shows Promising Results in Advanced Breast Cancer When Combined with Herceptin
11. Shire Announces Positive Results of Studies With Guanfacine Extended Release, An Investigational Nonstimulant Medication Filed for the Treatment of ADHD in Children and Adolescents
Post Your Comments:
(Date:12/22/2014)... 22, 2014 NxStage Medical, Inc. (NASDAQ: ... dialysis products, announced today that the U.S. Food ... One™ to perform hemodialysis overnight while the patient ... hemodialysis. NxStage,s® System One is the first and ... this indication. Home nocturnal hemodialysis ...
(Date:12/22/2014)... , Dec. 22, 2014 Research and Markets ... the "US Self-monitoring Blood Glucose Market" report ... This market insight focuses on the ... the United States . Reimbursement analysis and ... product analyses for more than 73 SMBG meters have ...
(Date:12/22/2014)... 2014 Research and Markets ( ... "Investment Analysis of the US Medical Device ... http://photos.prnewswire.com/prnh/20130307/600769 ... device sector identifies the key trends and rationale ... and mergers and acquisitions. The study ...
Breaking Medicine Technology:NxStage Receives FDA Clearance for Home Nocturnal Hemodialysis 2NxStage Receives FDA Clearance for Home Nocturnal Hemodialysis 3US Self-monitoring Blood Glucose Market 2Investment Analysis of the US Medical Device Sector 2
... Pa., Feb. 27, 2012 Auxilium Pharmaceuticals, Inc. (Nasdaq: ... participate in the 2012 Cowen Healthcare Conference to be ... in Boston.  Mr. Jim Fickenscher, Chief Financial Officer, is ... its product pipeline at 9:20 a.m. ET on Tuesday, ...
... (Pink Sheets: TROV.PK), a developer of trans-renal molecular diagnostics, ... to expand its business development activities and monetize the ... "Trovagene owns a significant portfolio of molecular diagnostic intellectual ... applications. While the company will focus its internal R&D ...
Cached Medicine Technology:Auxilium Pharmaceuticals to Present at the 2012 Cowen Healthcare Conference 2Auxilium Pharmaceuticals to Present at the 2012 Cowen Healthcare Conference 3Auxilium Pharmaceuticals to Present at the 2012 Cowen Healthcare Conference 4Trovagene Expands Business Development Efforts Through a Partnership with Leomics Associates, Inc. 2Trovagene Expands Business Development Efforts Through a Partnership with Leomics Associates, Inc. 3
(Date:12/25/2014)... BambooFlooringChina.com sells many bamboo products and the business is ... company announces big discounts on its bamboo mats , ... is the world’s leader in bamboo flooring. According to ... 20, 2015. , The bamboo mats are made from ... All the bamboo strips for the mats are boiled ...
(Date:12/25/2014)... December 25, 2014 Recently, LunaDress.co.uk has updated its ... and related accessories. Now, all of the models at LunaDress.co.uk come ... a groom lifts the wedding veil can turn out to be ... charm. A wedding veil can always bring surprise to a wedding. ... on how to choose veils for a big day . ...
(Date:12/25/2014)... (HealthDay News) -- Overeating is common during the holidays, but ... an expert says. "Don,t arrive at a party hungry. ... know you,ll be attending a party, but deprivation leads to ... at Northern Westchester Hospital in Mount Kisco, N.Y., said in ... during the day and even to have a snack before ...
(Date:12/25/2014)... AngelWeddingDress.com tries its best to translate the experience ... business has introduced its new collection of 2015 prom ... The new prom outfits are guaranteed to contain the ... are specially designed for 2015. Anyone who wants to ... its website before Jan. 26, 2015, the deadline of ...
(Date:12/25/2014)... California (PRWEB) December 25, 2014 Plugin ... of ProFire 5k. A fully customizable business presentation tool ... , “Adding the ProFire 5k business tool, users can ... Christina Austin, CEO of Pixel Film Studios. “ProFire 5k ... and style to add professionalism to a presentation” , ...
Breaking Medicine News(10 mins):Health News:Various Styles of Bamboo Mats in Many Colors from BambooFlooringChina.com 2Health News:LunaDress Provides Professional Tips On Shopping Wedding And Prom Dresses 2Health News:Angelweddingdress 2015 Prom Dresses Online Now 2Health News:Announcing a new ProFire 5k plugin from Pixel Film Studios for Final Cut Pro X Professionals 2
... Conseco, Inc. (NYSE:,CNO) today announced that it ... Partners II, L.P. to increase its percentage ownership ... response letter sent to Steel Partners by Conseco ... insurance companies help protect working American,families and seniors ...
... CRGN ) today announced that it had received ... regained compliance with the,requirements for continued listing on the ... In a letter dated January 28, 2008, NASDAQ ... 28, 2008 to regain compliance with,Marketplace Rule 4450(a)(5) by ...
... PORTLAND, Ore. New research from the Oregon Health ... may bring a wellspring of hope to many patients. ... kinds of DNA abnormalities that can occur in a ... with different kinds of acral and mucosal melanomas, which ...
... cochlear implant patients seen by Indiana University School of ... that cochlear implants in both ears significantly improves quality ... that the cost of the second implant is offset ... in the May issue of the journal Otolaryngology-Head and ...
... used to prepare a powerful cancer-killing agent may be ... the natural product attacks, according to findings published in ... Chemistry. , Building on their earlier research into neocarzinostatin, ... University of Wisconsin, Madison discovered that one of the ...
... goes to the Senate, SACRAMENTO, Calif., May ... in just as many years, the pro-assisted,suicide group ... 2747,(Berg/Levine). This new bill represents a strategy change ... their future efforts. As part of a,coordinated national ...
Cached Medicine News:Health News:Conseco Declines Proposal from Steel Partners II, L.P.; Proposal Would Reduce Conseco's Financial Flexibility and Potentially Disadvantage Other Shareholders 2Health News:Conseco Declines Proposal from Steel Partners II, L.P.; Proposal Would Reduce Conseco's Financial Flexibility and Potentially Disadvantage Other Shareholders 3Health News:Conseco Declines Proposal from Steel Partners II, L.P.; Proposal Would Reduce Conseco's Financial Flexibility and Potentially Disadvantage Other Shareholders 4Health News:CuraGen Corporation Regains NASDAQ Listing Compliance 2Health News:CuraGen Corporation Regains NASDAQ Listing Compliance 3Health News:OHSU Cancer Instutute researchers find abnormalities in gene for melanoma 2Health News:Bilateral cochlear implants: A case when 2 are definitely superior to 1 2Health News:Enzyme may hold key to improved targeting of cancer-fighting drugs 2Health News:Californians Against Assisted Suicide - Controversial Bill, AB 2747 Narrowly Passes Assembly 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: